NR4A1 and breast cancer: In 2019, the FDA approved the use of alpelisib in combination with fulvestrant for hormone receptor-positive and HER2-negative advanced breast cancer patients harboring PIK3CA-mutation suggesting the importance of inhibition of PI3K/AKT/mTOR axis in hormone receptor-positive breast cancers (21).